Market Context — Why This Technology, Why Now

The accelerating pace of biological discovery and therapeutic development demands tools that offer unparalleled control and efficiency. As research shifts towards personalized medicine and complex biological systems, the ability to precisely manipulate gene expression in a non-invasive, spatiotemporal manner becomes paramount. This technology aligns with the global push for advanced research automation and reproducibility, reducing reliance on manual processes and minimizing experimental variability, which are key drivers for adoption in competitive R&D environments worldwide.

Key Competitive Advantages
01

Enables precise gene expression induction in specific cells or tissues via light-activated ON/OFF switching, offering superior control compared to conventional drug-inducible systems.

02

Eliminates drug administration, minimizing cellular impact with light-based activation for rapid response. This simplifies experimental processes and enhances reproducibility.

03

Applicable as a gene manipulation tool across diverse fields including medicine, agriculture, and materials science, significantly accelerating R&D efficiency.

Market Opportunity
Life Science Research (Academia & Research Institutions)
$3.5B–$4.0B globally (AI est.)
Precise control systems are essential for gene function analysis and cell behavior observation in basic research. There is a high demand for improved research efficiency and reproducibility.
Academic research labs Government-funded research institutes Biotechnology research consortia
Pharmaceutical Development (Pharma Companies)
$5.5B–$6.0B globally (AI est.)
Applicable for functional analysis of target molecules in new drug development and for controlling the in vivo behavior of gene therapy drugs.
Major pharmaceutical R&D divisions Biotech firms developing gene therapies Contract research organizations (CROs)
Agriculture & Biofuel (Agri-Biotech Companies)
$2.0B–$2.5B globally (AI est.)
Applying optogenetic technology to crop transformation and metabolic pathway control in biofuel-producing microorganisms could enhance productivity and confer new functionalities.
Agricultural biotechnology corporations Biofuel production companies Specialty chemical producers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent establishes a robust scope of protection, covering the specific configuration of expression cassettes and the detailed characteristics of light-activatable fusion proteins across 21 claims. It successfully overcame two office actions through amendments and arguments, indicating strong validity and a broad technical scope that provides a secure foundation for licensees.

Competitive White Space

This patent focuses on the core light-activatable Tet expression system. White space exists in developing novel in vivo light delivery devices, integrating the system with advanced AI-driven experimental automation, or creating specialized cell-specific targeting mechanisms for the gene cassettes.

Economic Impact
~$80K/year estimated R&D cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

By utilizing this technology, companies could reduce time spent on experiment preparation and execution by 20% annually and improve experimental success rates by 10% compared to conventional gene expression control systems. For example, a research team with annual personnel costs of ~$335K (AI est.) conducting 500 experiments per year could reduce experiment time from 10 hours to 8 hours per experiment, potentially saving ~$65K (AI est.) in annual personnel costs (20% of ~$335K). Additionally, a reduction in re-experiments could save ~$15K (AI est.) in annual reagent costs. This totals an estimated annual economic impact of ~$80K (AI est.), enabling more research themes to be pursued concurrently.

Speed to Market
6× faster than in-house development
This technology has an established gene expression control mechanism using light-responsive proteins, with fundamental proof-of-principle already completed. Licensees can significantly shorten the R&D period required to develop an optogenetic system from scratch (approximately 3 years) and rapidly integrate it into existing gene manipulation platforms. Key components for gene expression control are clearly defined, allowing for efficient customization post-integration, with pilot deployment expected within approximately six months.
Competitive Positioning

X: Control Precision
Y: Application Versatility

Business Models & Applications
🧬 Toolkit Provision
Offer this technology as a light-responsive gene expression control kit to research institutions and pharmaceutical companies. This could simplify and streamline experiments, potentially capturing a broad user base.
🤝 Contract Research & Co-Development
Licensees could leverage this technology to provide contract research services for clients with specific gene expression control needs, or co-develop new gene therapy and regenerative medicine technologies.
💡 Platform Licensing
License this technology as a foundational gene expression control platform to companies across diverse industries. This strategy could contribute to their product development and research activities, maximizing revenue.
Adjacent Application Opportunities
🧠 Neuroscience
Optogenetic Neuron Activity Modulation
Introducing this system into neurons in specific brain regions could enable ON/OFF control of neural activity via light. This has the potential to advance functional analysis of neural circuits and contribute to understanding neurodegenerative disease mechanisms like Alzheimer's and Parkinson's, potentially improving research efficiency by 20%.
♻️ Environmental Biotechnology
Light-Inducible Bioremediation
Introducing this system into microorganisms that degrade environmental pollutants could allow light-controlled production of degrading enzymes. This could enable adjustment of degradation capacity based on site conditions, potentially accelerating cleanup times by 30% for efficient and safe environmental remediation.
💉 Regenerative Medicine
Optogenetic Stem Cell Differentiation Induction
Introducing this system into stem cells could induce specific differentiation factors via light irradiation. This offers precise control over cell growth and differentiation processes in tissue regeneration and artificial organ development, potentially improving cell sheet quality by 25%.
Integration Roadmap — Estimated 24-Month Deployment
Basic Validation & Prototype Development
Duration: 6 months
Construction of the foundational gene expression cassette and validation of light responsiveness in target cell systems. Conduct proof-of-concept and functional evaluation of the prototype.
System Optimization & Application Development
Duration: 9 months
Optimization of light irradiation conditions and gene delivery methods tailored to target applications. Conduct system design and initial evaluation for scalability.
Demonstration & Commercialization Phase
Duration: 9 months
Final demonstration testing for integration into licensee products or research processes. Advance pilot deployment and prepare for market rollout.
Technical Feasibility
This technology comprises gene expression cassettes and genes encoding fusion proteins, enabling introduction into cells via existing gene delivery techniques (e.g., viral vectors, transfection). It does not require specialized hardware beyond a light irradiation device and standard cell culture equipment, indicating high compatibility with existing bio-research infrastructure and low technical implementation hurdles.
Success Scenario
Implementing this technology could enable instantaneous and localized ON/OFF control of gene expression via light irradiation, replacing complex drug concentration adjustments and prolonged culture periods in traditional experiments. This is estimated to improve experimental reproducibility and shorten R&D cycles by up to 30%.
Patent Record
APPLICATION NO.
特願2020-539642
REGISTRATION NO.
7474512
FILING DATE
2019/08/30
GRANT DATE
2024/04/17
EXPIRATION DATE
2039/08/30
PATENT HOLDER
国立研究開発法人科学技術振興機構
Examination History
2022年05月17日
出願審査請求書
2023年07月04日
拒絶理由通知書
2023年09月04日
手続補正書(自発・内容)
2023年11月21日
拒絶理由通知書
2024年01月17日
手続補正書(自発・内容)
2024年01月17日
意見書
2024年03月12日
特許査定